Timeline
Health & Bio Today: ValiRx walks away from Stingray licence, Verici Dx, Inspiration Healthcare, Hammerson
ValiRx shares tumbled after Stingray evaluation ends
ValiRx exercises RNA option after evaluation finishes four months early
Health & Bio Today: ImmuPharma narrows loss with P140 partnership push, Physiomics, ValiRx, AstraZeneca
ValiRx's Cytolytix secures European patent for nanoparticle delivery
ValiRx raises up to £1.155m to fund McGill in‑licence, Cytolytix preclinical work and animal‑health expansion
More in Telecoms
Helios Towers upgrades 2026 guidance after record tenancy growth
The independent mobile tower operator added a record 2,511 tenancies in the first half, lifting Adjusted EBITDA 14% and prompting a second guidance upgrade alongside its first-ever dividend.